189 related articles for article (PubMed ID: 15720210)
1. Small interfering RNAs and antisense oligonucleotides for treatment of neurological diseases.
Forte A; Cipollaro M; Cascino A; Galderisi U
Curr Drug Targets; 2005 Feb; 6(1):21-9. PubMed ID: 15720210
[TBL] [Abstract][Full Text] [Related]
2. Liver as a target for oligonucleotide therapeutics.
Sehgal A; Vaishnaw A; Fitzgerald K
J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
[TBL] [Abstract][Full Text] [Related]
3. Antisense therapeutics and the treatment of CNS disease.
Jaeger LB; Banks WA
Front Biosci; 2004 May; 9():1720-7. PubMed ID: 14977581
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of Antisense Drugs.
Bennett CF; Baker BF; Pham N; Swayze E; Geary RS
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():81-105. PubMed ID: 27732800
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotides in therapy for neurodegenerative disorders.
Evers MM; Toonen LJ; van Roon-Mom WM
Adv Drug Deliv Rev; 2015 Jun; 87():90-103. PubMed ID: 25797014
[TBL] [Abstract][Full Text] [Related]
6. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs.
Shen X; Corey DR
Nucleic Acids Res; 2018 Feb; 46(4):1584-1600. PubMed ID: 29240946
[TBL] [Abstract][Full Text] [Related]
7. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
[TBL] [Abstract][Full Text] [Related]
8. Antisense therapies in neurological diseases.
Brunet de Courssou JB; Durr A; Adams D; Corvol JC; Mariani LL
Brain; 2022 Apr; 145(3):816-831. PubMed ID: 35286370
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases.
Southwell AL; Skotte NH; Bennett CF; Hayden MR
Trends Mol Med; 2012 Nov; 18(11):634-43. PubMed ID: 23026741
[TBL] [Abstract][Full Text] [Related]
10. Antisense and RNA interference approaches to target validation in pain research.
Kurreck J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):179-87. PubMed ID: 15603251
[TBL] [Abstract][Full Text] [Related]
11. Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System.
Mendonça MCP; Kont A; Aburto MR; Cryan JF; O'Driscoll CM
Mol Pharm; 2021 Apr; 18(4):1491-1506. PubMed ID: 33734715
[TBL] [Abstract][Full Text] [Related]
12. Translating Antisense Technology into a Treatment for Huntington's Disease.
Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
[TBL] [Abstract][Full Text] [Related]
13. Small non-coding RNA therapeutics for cardiovascular disease.
Shah AM; Giacca M
Eur Heart J; 2022 Nov; 43(43):4548-4561. PubMed ID: 36106499
[TBL] [Abstract][Full Text] [Related]
14. Oligonucleotide-based therapy for neurodegenerative diseases.
Magen I; Hornstein E
Brain Res; 2014 Oct; 1584():116-28. PubMed ID: 24727531
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotides: the state of the art.
Aboul-Fadl T
Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780
[TBL] [Abstract][Full Text] [Related]
16. Oligonucleotide delivery: a patent review (2010 - 2013).
Grijalvo S; Aviñó A; Eritja R
Expert Opin Ther Pat; 2014 Jul; 24(7):801-19. PubMed ID: 24798406
[TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotides for the treatment of dyslipidaemia.
Visser ME; Witztum JL; Stroes ES; Kastelein JJ
Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
[TBL] [Abstract][Full Text] [Related]
18. Synthetic oligonucleotides as therapeutics: the coming of age.
Ma DD; Rede T; Naqvi NA; Cook PD
Biotechnol Annu Rev; 2000; 5():155-96. PubMed ID: 10875000
[TBL] [Abstract][Full Text] [Related]
19. Antisense therapy in oncology: new hope for an old idea?
Tamm I; Dörken B; Hartmann G
Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
[TBL] [Abstract][Full Text] [Related]
20. Gene therapy for neurological disorders.
Choong CJ; Baba K; Mochizuki H
Expert Opin Biol Ther; 2016; 16(2):143-59. PubMed ID: 26642082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]